NCT04840992View on ClinicalTrials.gov

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

840

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

July 8, 2022

Study Completion Date

August 9, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation

Aerogen Solo

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular administration

BIOLOGICAL

Placebo for Inhalation

Aerogen Solo

BIOLOGICAL

Placebo

Intramuscular administration

Trial Locations (1)

Unknown

Jiangsu Provincal Center for Disease Control and Prevention, Nanjing

Sponsors
All Listed Sponsors
collaborator

Beijing Institute of Biotechnology

OTHER

collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

lead

CanSino Biologics Inc.

INDUSTRY

NCT04840992 - Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation | Biotech Hunter | Biotech Hunter